All Issue

2021 Vol.2, Issue 4

Review article

31 December 2021. pp. 123-127
Abstract
Sorry, not available.
Click the PDF button.
References
1
Jefferson A et al., Sexually transmitted Neisseria gonorrhoeae Infections- Update on drug treatment and vaccine developmet, Medicines, 2021 10.3390/medicines802001133562607PMC7914478
2
Centers for Disease Control, Increases in fluoroquinolone-resistant Neisseria gonorrhoeae-Hawaii and California, 2001, MMWR, 2002
3
Shimuta K et al., Emergence and evolution of internationally disseminated cephalosporin-resistant Neisseria gonorrhoeae clones from 1995 to 2005 in Japan, BMC Infect Dis, 2015 10.1186/s12879-015-1110-x26381611PMC4574456
4
Public Health England, UK case of Neisseria gonorrhoeae with high-level resistance to azithromycin and resistance to ceftriaxone acquired abroad, Health Protection Report; Public Health England, London, UK, volume 12, 2018
5
Centers for Disease Control, Update to CDC'S treatment guidelines for gonococcal infection, MMWR, 2020
6
Jacobsson S et al., High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South Africa (2015-2017), Antimicrob Agents Chemother, 2019 10.1128/AAC.01479-1931548184PMC6879270
7
Taylor SN et al., Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea, N Engl J Med, 2018 10.1056/NEJMoa170698830403954
8
Golparian D et al., In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?, Antimicrob Agents Chemother, 2012 10.1128/AAC.00036-1222354296PMC3346660
9
Hook EW et al., A phase 2 trial of oral solithromycin 1200 mg or 1000 mg as single-dose oral therapy for uncomplicated gonorrhea, Clin Infect Dis, 2015 10.1093/cid/civ47826089222
10
Jacobsson S et al., In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae, J Antimicrob Chemother, 2018 10.1093/jac/dky16229796611PMC6927889
11
Taylor SN et al., Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation, Clin Infect Dis, 2018 10.1093/cid/ciy14529617982PMC6070052
12
Pizza M et al., Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing, Science, 2000 10.1126/science.287.5459.181610710308
Information
  • Publisher :The Association of Korean Urologists
  • Publisher(Ko) :대한비뇨의학과의사회
  • Journal Title :비뇨의학 Urology Digest
  • Volume : 2
  • No :4
  • Pages :123-127